Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.

Also called NCT01289119

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 506 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01289119
  • WHO UTN U1111-1118-3681
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Hong Kong SAR China, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01289119. Randomized; quadruple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2013-03-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Alogliptin
Intervention (Drug)
Placebo to alogliptin
Intervention (Drug)
Metformin
Intervention (Drug)
Pioglitazone
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01289119
Content hash
571a7b4ee6788b8fc2b4dc3be7d5b4b7216fc099d9ce915752b1e8cb73ac6f87